JP2015512406A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512406A5 JP2015512406A5 JP2015503465A JP2015503465A JP2015512406A5 JP 2015512406 A5 JP2015512406 A5 JP 2015512406A5 JP 2015503465 A JP2015503465 A JP 2015503465A JP 2015503465 A JP2015503465 A JP 2015503465A JP 2015512406 A5 JP2015512406 A5 JP 2015512406A5
- Authority
- JP
- Japan
- Prior art keywords
- amount
- laquinimod
- pharmaceutically acceptable
- dmf
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical group COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 claims 17
- 229960004419 dimethyl fumarate Drugs 0.000 claims 16
- 229960004577 laquinimod Drugs 0.000 claims 16
- GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical compound OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 12
- 201000006417 multiple sclerosis Diseases 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 206010071068 Clinically isolated syndrome Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 4
- 238000009825 accumulation Methods 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 206010061818 Disease progression Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000005750 disease progression Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000024806 Brain atrophy Diseases 0.000 claims 1
- 208000032862 Clinical Deterioration Diseases 0.000 claims 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
- 238000011360 adjunctive therapy Methods 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000009266 disease activity Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 150000002344 gold compounds Chemical class 0.000 claims 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims 1
- 229960004171 hydroxychloroquine Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
- 229960001940 sulfasalazine Drugs 0.000 claims 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616337P | 2012-03-27 | 2012-03-27 | |
| US61/616,337 | 2012-03-27 | ||
| US13/800,047 | 2013-03-13 | ||
| US13/800,047 US20130259856A1 (en) | 2012-03-27 | 2013-03-13 | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| PCT/US2013/033885 WO2013148690A1 (en) | 2012-03-27 | 2013-03-26 | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017104051A Division JP2017200927A (ja) | 2012-03-27 | 2017-05-26 | ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015512406A JP2015512406A (ja) | 2015-04-27 |
| JP2015512406A5 true JP2015512406A5 (https=) | 2016-05-19 |
Family
ID=49235339
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503465A Withdrawn JP2015512406A (ja) | 2012-03-27 | 2013-03-26 | ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療 |
| JP2017104051A Withdrawn JP2017200927A (ja) | 2012-03-27 | 2017-05-26 | ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017104051A Withdrawn JP2017200927A (ja) | 2012-03-27 | 2017-05-26 | ラキニモドおよびフマル酸ジメチルを併用した多発性硬化症の治療 |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US20130259856A1 (https=) |
| EP (1) | EP2830623A4 (https=) |
| JP (2) | JP2015512406A (https=) |
| KR (1) | KR20150003765A (https=) |
| CN (2) | CN105853422A (https=) |
| AR (1) | AR090491A1 (https=) |
| AU (2) | AU2013239850A1 (https=) |
| CA (1) | CA2868259A1 (https=) |
| EA (1) | EA201491773A1 (https=) |
| HK (1) | HK1205941A1 (https=) |
| IL (1) | IL234687A0 (https=) |
| MX (1) | MX2014011616A (https=) |
| SG (2) | SG10201607976WA (https=) |
| TW (1) | TW201343164A (https=) |
| UY (1) | UY34720A (https=) |
| WO (1) | WO2013148690A1 (https=) |
| ZA (1) | ZA201407722B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2554347C2 (ru) | 2008-08-19 | 2015-06-27 | Ксенопорт, Инк. | Пролекарства метилгидрофумарата, фармацевтические композиции с ними и способы применения |
| CA2851525A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| CN104093310A (zh) | 2012-02-03 | 2014-10-08 | 泰华制药工业有限公司 | 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途 |
| JP6215238B2 (ja) | 2012-02-16 | 2017-10-18 | テバ ファーマシューティカル インダストリーズ リミティド | Ｎ−エチル−ｎ−フェニル−１，２−ジヒドロ−４，５−ジ−ヒドロキシ−１−メチル−２−オキソ−３−キノリンカルボキサミド、その製剤、および使用 |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| EP2692343A1 (en) * | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| CA2882730C (en) | 2012-08-22 | 2019-12-31 | Arbor Pharmaceuticals, Llc | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| US10945984B2 (en) | 2012-08-22 | 2021-03-16 | Arbor Pharmaceuticals, Llc | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| EP2916915A4 (en) | 2012-11-07 | 2016-06-22 | Teva Pharma | LAQUINIMOD AMINE SALTS |
| US20160046582A1 (en) | 2013-03-14 | 2016-02-18 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| US9416096B2 (en) | 2013-09-06 | 2016-08-16 | Xenoport, Inc. | Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use |
| ES2713157T3 (es) | 2014-02-28 | 2019-05-20 | Banner Life Sciences Llc | Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| WO2015168103A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| KR20200013086A (ko) | 2014-12-11 | 2020-02-05 | 액테리온 파마슈티칼 리미티드 | 선택적 s1p1 수용체 효능제에 대한 투약 섭생 |
| MA41139B1 (fr) | 2014-12-11 | 2026-02-27 | Laboratoires Juvise Pharmaceuticals | Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque |
| GB2540163A (en) * | 2015-07-07 | 2017-01-11 | Univ London Queen Mary | Combination therapy for treating multiple sclerosis |
| WO2017120355A1 (en) * | 2016-01-06 | 2017-07-13 | Teva Pharmaceutical Industries Ltd. | Dihydroquinolines and uses thereof |
| US11903918B2 (en) | 2020-01-10 | 2024-02-20 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| US12483171B2 (en) | 2023-12-18 | 2025-11-25 | Abb Schweiz Ag | Plug and play solid state controller for high efficiency motors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| WO2007006308A1 (en) * | 2005-07-07 | 2007-01-18 | Aditech Pharma Ab | Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use |
| NZ567088A (en) | 2005-10-19 | 2012-06-29 | Teva Pharma | Crystals of laquinimod sodium, and process for the manufacture thereof |
| KR20150065951A (ko) | 2006-06-12 | 2015-06-15 | 테바 파마슈티컬 인더스트리즈 리미티드 | 안정한 라퀴니모드 제제 |
| EP2680010A1 (en) * | 2007-02-08 | 2014-01-01 | Biogen Idec MA Inc. | Nrf2 screening assays and related methods and compositions |
| ES2599227T3 (es) * | 2007-02-08 | 2017-01-31 | Biogen Ma Inc. | Neuroprotección en enfermedades desmielinizantes |
| US20100260755A1 (en) * | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
| JP2012525385A (ja) * | 2009-04-29 | 2012-10-22 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 神経変性および神経炎症の治療 |
| JP2012530701A (ja) * | 2009-06-19 | 2012-12-06 | テバ ファーマシューティカル インダストリーズ リミティド | 多発性硬化症のラキニモドでの治療 |
| EP2982371A1 (en) | 2010-02-12 | 2016-02-10 | Biogen MA Inc. | Dimethyl fumarate with glatiramer acetate or interferon-beta for treating multiple sclerosis |
| MX340734B (es) * | 2011-01-25 | 2016-07-22 | Novartis Ag | Sistemas y metodos de captura y formacion de imagenes de movimiento para uso medico. |
| AR090885A1 (es) * | 2012-05-02 | 2014-12-10 | Teva Pharma | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple |
-
2013
- 2013-03-13 US US13/800,047 patent/US20130259856A1/en not_active Abandoned
- 2013-03-25 AR ARP130100966 patent/AR090491A1/es unknown
- 2013-03-25 TW TW102110549A patent/TW201343164A/zh unknown
- 2013-03-26 SG SG10201607976WA patent/SG10201607976WA/en unknown
- 2013-03-26 HK HK15106555.7A patent/HK1205941A1/xx unknown
- 2013-03-26 CN CN201610252021.1A patent/CN105853422A/zh active Pending
- 2013-03-26 WO PCT/US2013/033885 patent/WO2013148690A1/en not_active Ceased
- 2013-03-26 SG SG11201405755QA patent/SG11201405755QA/en unknown
- 2013-03-26 KR KR20147030064A patent/KR20150003765A/ko not_active Withdrawn
- 2013-03-26 EA EA201491773A patent/EA201491773A1/ru unknown
- 2013-03-26 JP JP2015503465A patent/JP2015512406A/ja not_active Withdrawn
- 2013-03-26 CN CN201380016933.3A patent/CN104470520A/zh active Pending
- 2013-03-26 MX MX2014011616A patent/MX2014011616A/es unknown
- 2013-03-26 EP EP13768294.4A patent/EP2830623A4/en not_active Withdrawn
- 2013-03-26 CA CA 2868259 patent/CA2868259A1/en not_active Abandoned
- 2013-03-26 AU AU2013239850A patent/AU2013239850A1/en not_active Abandoned
- 2013-04-02 UY UY34720A patent/UY34720A/es not_active Application Discontinuation
-
2014
- 2014-09-16 IL IL234687A patent/IL234687A0/en unknown
- 2014-10-23 ZA ZA2014/07722A patent/ZA201407722B/en unknown
-
2015
- 2015-01-05 US US14/589,684 patent/US20150119420A1/en not_active Abandoned
- 2015-09-14 US US14/853,826 patent/US20160000774A1/en not_active Abandoned
-
2017
- 2017-04-24 US US15/495,406 patent/US20170224675A1/en not_active Abandoned
- 2017-05-26 JP JP2017104051A patent/JP2017200927A/ja not_active Withdrawn
- 2017-07-27 US US15/662,165 patent/US20170319570A1/en not_active Abandoned
- 2017-11-03 US US15/803,017 patent/US20180050031A1/en not_active Abandoned
-
2018
- 2018-01-04 AU AU2018200065A patent/AU2018200065A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512406A5 (https=) | ||
| HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
| JP2009536176A5 (https=) | ||
| JP2011173928A5 (https=) | ||
| JP2017528507A5 (https=) | ||
| JP2010518122A5 (https=) | ||
| JP2014526503A5 (https=) | ||
| JP2010525050A5 (https=) | ||
| CN103732062A (zh) | 治疗多发性硬化以及保持和/或增加髓磷脂含量的方法 | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2015532296A5 (https=) | ||
| JP2014513123A5 (https=) | ||
| JP2017222722A5 (https=) | ||
| JP2015522077A5 (https=) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| JP2020500864A5 (https=) | ||
| JP2017533220A5 (https=) | ||
| JP2021512906A5 (https=) | ||
| JP2016507500A5 (https=) | ||
| JP2019507786A5 (https=) | ||
| JP2017533956A (ja) | 筋肉痛を含む病態の治療のための組合せ | |
| JP6433980B2 (ja) | Ｎｓａｉｄ投与並びに関連する組成物、方法及びシステム | |
| JP2023531930A5 (https=) | ||
| JP2018529747A5 (https=) | ||
| JP6885649B2 (ja) | 統合失調症の治療のためのイロペリドン |